Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orionis Biosciences
Biotech
Novartis sticks 2nd deal with Orionis, this one worth up to $1.4B
Novartis stuck a second deal with Orionis, this time handing $40 million to the molecular glue biotech to work on “challenging therapeutic targets.”
James Waldron
Jun 10, 2026 8:21am
Bayer radiology head takes top U.S. pharma spot—Chutes & Ladders
Apr 3, 2026 8:30am
Genentech sticks 2nd molecular glue deal with Orionis worth $2B
May 21, 2025 8:30am
Genentech pays $47M upfront for Orionis molecular glue deal
Sep 20, 2023 8:53am
Ayala, Advaxis merger means new leadership team—Chutes & Ladders
Oct 21, 2022 9:30am
Novartis taps Orionis to pursue 'historically elusive targets'
Mar 5, 2020 9:20am
